OncoMatch/Clinical Trials/NCT06854159
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
Is NCT06854159 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Chimeric Antigen Receptor T-Cell Therapy and Odronextamab for recurrent diffuse large b-cell lymphoma.
Treatment: Chimeric Antigen Receptor T-Cell Therapy · Odronextamab — This phase II trial tests how well odronextamab works before and after standard of care (SOC) chimeric antigen receptor (CAR) T-cell therapy in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). CAR-T cell therapy is the SOC treatment most patients receive when other treatments have failed. CAR-T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Odronextamab is a monoclonal antibody that is called bispecific, as it individually targets 2 cell proteins, CD20 and CD3. Proteins are part of each cell in the body, which work together like little machines for the cell to function. CD20 is a protein that is found on the surface of both normal B-cells and B-cells that make up certain cancers, like DLBCL. CD3 is a protein that is found on the surface of T cells. T-cells and normal B-cells are types of white blood cells in the body and are a part of the immune system that fights infections. Odronextamab is designed to help T-cells find and kill the B-cells including the cancer cells in DLBCL. Giving odronextamab before and after CAR T-cell therapy may improve response in patients with relapsed or refractory DLBCL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Leukocytes ≥ 2,500/µL; ANC ≥ 1,000/µL or > 500/µL for bone marrow involvement; Platelets ≥ 50,000/µL or ≥ 25,000/µL for bone marrow involvement; Hemoglobin ≥ 8 g/dL or ≥ 7 g/dL for bone marrow involvement
Kidney function
Creatinine clearance ≥ 30 mL/min/1.73 m^2 by Cockcroft-Gault; Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 mL/min
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert disease, ≤ 4 x ULN for Gilbert syndrome excluded); AST/ALT ≤ 3 x ULN (≤ 5 x ULN for liver involvement); Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN for liver involvement or bone metastases)
Cardiac function
Cardiac ejection fraction > 50% by echocardiogram or MUGA scan
Leukocytes ≥ 2,500/µL; ANC ≥ 1,000/µL or > 500/µL for patients with bone marrow involvement; Platelets ≥ 50,000/µL or ≥ 25,000/µL for patients with bone marrow involvement; Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert disease, ≤ 4 x ULN for Gilbert syndrome excluded); AST/ALT ≤ 3 x ULN (≤ 5 x ULN for liver involvement); Creatinine clearance ≥ 30 mL/min/1.73 m^2 by Cockcroft-Gault; Hemoglobin ≥ 8 g/dL or ≥ 7 g/dL for bone marrow involvement; Alkaline phosphatase ≤ 2.5 x ULN (≤ 5 x ULN for liver involvement or bone metastases); INR and aPTT ≤ 1.5 x ULN; Cardiac ejection fraction > 50% by echocardiogram or MUGA scan; Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06854159 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify